Vall D Hebron Institute Of Oncology — Clinical Trial Site

48 Registered trials

21 Currently recruiting

Organisation

Vall D Hebron Institute Of Oncology

Location

Barcelona, Spain

Identifier

ORG-100011442

Address

Calle Natzaret 115, 08035, Spain

Departments

1201:Servicio de Oncología y Hematología Pediátrica
Dep. of oncology
Department of Gynecology
Department of Hematology
Early Drug Development Unit
Early Drug Development Unit-UITM
Gastrointestinal and Endocrine Tumors Group
Hematology
Medical Oncology
Medical Oncology Departmnent
Medical Oncology- Phase 1 Clinical Trials Unit
Nephrology
Oncología
Oncología Médica
Oncology
Oncology Department
Oncology Service
Paediatric Haematology and Oncology Service
Servei d'Hematologia
Servicio de Oncología Médica
Traumatology
Unidad Investigacion Terapia Molecular - VHIO
Vall d’Hebron Institute of Oncology (VHIO)

Clinical trials at this site (48)

Search interface

A Study of Sigvotatug Vedotin in Advanced Solid Tumors Recruiting

2023-508469-34-00 Esophageal cancer 1 2020-10-14
POST-SURGICAL LIQUID BIOPSY - GUIDED TREATMENT OF STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS - THE PEGASUS STUDY Ended

2024-517704-10-00 Colon cancer 4 2024-09-30
A Phase I study of STA551 and STA551 in combination with atezolizumab in patients with solid tumours Ended

2023-508764-30-00 Locally advanced or metastatic solid tumors 1 2024-07-31
Phase II Study of Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-Low Breast Cancer Patients Presenting with Newly Diagnosed or Progressing… Ended

2023-506702-39-00 HER2-low breast cancer presenting with newly diagnosed 4 2024-06-05
Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC): Evaluation of the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Co… Ended

2022-502948-13-00 Hepatocellular Carcinoma 4 2024-03-01
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Ended

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
DAREON™-7: A study to test how well different doses of BI 764532 in addition to chemotherapy are tolerated by people with advanced neuroendo… Ended

2023-505870-13-00 Extra-pulmonary neuroendocrine carcinoma (epNEC) 3 2024-01-11
A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combina… Ended

2023-510307-22-00 Advanced head and neck cancer 1 2021-09-24
Study of BGB-11417 in Patients with Mature B Cell Malignancies Ended

2024-515592-35-00 Mature B Cell Malignancies 1 2021-06-14
Rollover Study for Patients with Sickle Cell Disease who have Completed a prior Novartis-Sponsored Crizanlizumab Study Ended

2024-510734-41-00 Sickle cell disease 6 2021-06-10
Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Sub… Ended

2023-508281-15-00 Locally Advanced or Metastatic Solid Tumors 1 2020-11-10
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant versus Placebo Plus Palbociclib and Fulvestrant in… Ended

2023-505812-39-00 HR+/HER2-Negative Locally Advanced or Metastatic Breast 5 2020-08-28
Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study) Ended

2022-502604-67-00 Malignant pleural mesothelioma (MPM) 10 2019-12-20
A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in pati… Ended

2023-509463-24-01 metastatic pancreatic cancer 4 2019-11-04
Dose Escalation and Dose Expansion Study of PD1-LAG3 Bispecific Antibody in Patients with Advanced and/or Metastatic Solid Tumors Ended

2023-503425-18-00 Metastatic Solid Tumors 1 2019-10-02
Study for patients with Primary Hyperoxaluria to evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection Ended

2024-512260-54-00 Primary Hyperoxaluria 5 2019-08-20
A study to investigate the clinical benefit of isatuximab in combination with bortezomib, lenalidomide and dexamethasone in adults with newl… Ended

2024-514417-34-00 Cancer 5 2017-12-14
An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination wi… Ended

2024-512670-10-00 Unresectable or Metastatic Melanoma 9 2025-02-13
Trial to assess the safety and preliminary efficacy of GEN1055 on malignant solid tumors as monotherapy and as combination therapy. Ended

2023-507049-28-00 Malignant Solid Tumors 7 2024-04-16
A MULTICENTER, SINGLE-ARM, THREE COHORT, PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HE… Ended

2023-503251-10-00 Metastatic Breast Cancer or Advanced Non-Small Cell Lun 4 2023-10-10
Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhi… Ended

2022-500652-37-00 Advanced melanoma refractory to prior checkpoint inhibi 4 2022-12-01
Brightline-1: A study to compare brigimadlin (BI 907828) with doxorubicin in people with a type of cancer called dedifferentiated liposarcom… Ended

2024-511361-11-00 Advanced dedifferentiated liposarcoma 10 2022-03-25
A study to test different doses of BI 1823911 alone and combined with other medicines in people with different types of advanced cancer with… Ended

2024-512805-18-00 solid tumour harbouring G12C mutation 3 2021-08-03
Clinical Trial of Lenvatinib, Pembrolizumab, and Standard Chemotherapy for Head and Neck Squamous Cell Carcinoma That has Returned or Spread Ended

2022-500820-31-00 Recurrent or metastatic squamous cell carcinoma of the 4 2020-07-16